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IntroducLon	  
•  Co-IP  
•  Use DAX-1 antibody attached to magnetic beads to pull down DAX-1 protein from whole 
cell lysate.  
•  Follow with SDS-PAGE electrophoresis and Western Blot analysis to determine presence 
of SUMOylation on DAX-1 protein. 
•  Mutagenesis 
•  Use PCR mutagenesis of key lysine (K) amino acid residues in DAX-1 gene sequence 
using Stratagene QuickChange Lightning Site-Directed Mutagenesis kit. Lysine residues 
were changed to alanine. 
•  Analyze Mutants via in vitro SUMOylation 
•  Express wild-type and mutant DAX-1 protein using cell-free expression via TnT Quick 
Coupled Transcription/Translation System. 
•  Carryout in vitro SUMOylation using ENZO SUMOylation Kit. 
•  Follow up with SDS-PAGE electrophoresis and Western Blot analysis to determine 
SUMOylation status of mutants.  
•  Transfection of mutants and Assay of gene expression changes 
•  Transfect wild-type and mutant DAX-1 into cell lines. 
•  Assay presence of DAX-1 using mRNA and protein. 
•  Explore expression profile of wild-type and mutants. 
Methods	  and	  Materials	  
The	  DAX-­‐1	  protein	  was	  SUMOylated	  for	  all	  cell	  lines	  tested.	  When	  the	  putaCve	  SUMO	  sites	  
were	  mutated,	  the	  mutant	  DAX-­‐1	  protein	  expressed,	  and	  SUMOylated	  in	  vitro	  a	  reducCon	  
in	  SUMOylaCon	  level	  and	  an	  overall	  reducCon	  in	  DAX-­‐1	  level	  was	  observed.	  
	  
When	  the	  SUMO	  mutant	  DAX-­‐1	  plasmids	  were	  transfected	  into	  cells	  with	  low	  endogenous	  
DAX-­‐1	  levels	  we	  saw	  diﬀerences	  between	  the	  WT	  and	  mutant	  samples.	  WT	  DAX-­‐1	  reduced	  
ERα	  and	  Cyclin	  D1	  levels,	  some	  of	  that	  reducCon	  was	  lost	  with	  the	  mutants	  indicaCng	  that	  
without	  SUMOylaCon	  on	  DAX-­‐1,	  DAX-­‐1	  is	  less	  able	  to	  carryout	  normal	  funcCons.	  We	  saw	  a	  
similar	  result	  with	  downstream	  proliferaCon	  genes.	  	  
	  
SUMOylaCon	  may	  be	  an	  important	  modiﬁcaCon	  that	  acts	  as	  a	  stabilizing	  factor,	  which	  
allows	  DAX-­‐1	  to	  funcCon	  properly	  in	  the	  cell.	  	  
Discussion	  and	  Conclusions	  
  DAX-1 (Dosage Sensitive Sex Reversal Adrenal Hypoplasia Congenita on the X 
Chromosome, gene 1) is a member of the Nuclear Hormone Receptor superfamily.  
DAX-1 is classified as an orphan “sub-type” of nuclear receptor since, to date, no 
known ligand has been identified that is able to bind to the DAX-1 protein.  Studies 
have shown that DAX-1 plays a key role early on in mammalian sex determination as 
well as in the expression of steroid hormones.  Notably, mutation of the human DAX-1 
gene results in a disorder that leads to the failure of the adrenal gland to properly 
develop called adrenal hypoplasia congenita (AHC).  This disorder is fatal if left 
untreated.  Furthermore, duplication or over-expression of the DAX-1 gene in humans 
results in individuals that are male by genotype (i.e. have X and Y chromosomes), but 
are phenotypically female. This is a phenotype known as dosage sensitive sex-
reversal (DSS).  More recently, DAX-1 has been shown to play a role in regulating 
growth of cancer cells, however the precise molecular mechanism of DAX-1 control is 
not well characterized.  For example, in some types of cancer DAX-1 expression is 
upregulated, while in others it’s expression is highly downregulated or completely 
absent. In an effort to better understand DAX-1 function both in normal and disease 
states we are examining one type of posttranslational modification, SUMOylation. 
SUMOylation involves the addition of the small polypeptide conjugate SUMO (Small 
Ubiquitin-like Modifier) to proteins. SUMO is similar to Ubiquitin in that it is a small 
polypeptide, which can be covalently linked to a target protein by an isopeptide bond 
and that bond formation requires an enzyme pathway. However, they differ greatly in 
their functions; ubiquitin tags proteins for degradation whereas SUMO can have a 
variety of effects including changes in localization, protein-protein interaction, 
interaction with DNA, and in some cases stabilization of the target protein.  
SUMOylation of nuclear hormone receptors can have profound effects on their 
function. To study the effects of SUMOylation on DAX-1, the overall SUMOylation 
status of DAX-1 in mammalian cell lines was determined. It was found that DAX-1 is 
SUMOylated in several cell lines, both normal and carcinoma cells. Mutations were 
made in predicted SUMOylation sites within the DAX-1 gene that were identified using 
the SUMOsp 2.0 program program.  Mutants were transfected into mammalian cell 
lines and assayed for changes in gene expression and activity.  Here, we present the 
results of these experiments. 
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Co-­‐IP	  for	  DAX-­‐1	  and	  SUMOs	  in	  human	  cell	  lines.	  A549:	  lung	  carcinoma,	  SW13:	  adrenal	  carcinoma,	  MDA-­‐MB	  231:	  triple	  
negaCve	  breast	  adenocarcinoma,	  MCF7:	  ER	  posiCve	  breast	  	  adenocarcinoma,	  MCF10A:	  normal	  breast.	  SUMO	  was	  present	  
on	  DAX-­‐1	  in	  all	  cell	  lines	  assayed.	  	  
SUMO-1  
WT     249     DM 
A:	  Amino	  acid	  sequence	  of	  DAX-­‐1,	  putaCve	  SUMOylaton	  sites	  in	  red,	  bolded	  K	  (lysine)	  is	  key	  residue	  for	  aqachment	  of	  SUMO,	  K249	  
and	  K362	  most	  likely	  SUMOylaCon	  sites	  B:	  Map	  of	  DAX-­‐1	  with	  locaCon	  of	  putaCve	  sites	  C:	  PCR	  mutagenesis	  diagram,	  used	  to	  create	  
mutaCons	  at	  putaCve	  sites.	  D,E,F	  Wild-­‐type	  and	  SUMO	  mutant	  DAX-­‐1	  proteins	  were	  expression	  via	  the	  TnT	  cell	  free	  expression	  
system,	  protein	  was	  then	  SUMOylated	  in	  vitro	  using	  SUMOylaCon	  kit	  D:	  Blot	  for	  SUMO-­‐1	  E:	  Blot	  for	  SUMO-­‐2	  and	  SUMO-­‐3	  F:	  Blot	  for	  
DAX-­‐1	  	  
Enzyme pathway for SUMOylation of target proteins. E1: activating 
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DAX-­‐1	  was	  transfected	  into	  MCF7	  breast	  cancer	  cells.	  A:	  Standard	  RT-­‐PCR	  B:	  qPCR	  results	  for	  transfecCon	  C:	  Luciferase	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Wild-­‐type	  or	  SUMO	  mutant	  DAX-­‐1	  genes	  were	  transfected	  into	  MCF7	  breast	  cancer	  cells.	  A:	  mRNA	  	  conﬁrmaCon	  of	  transfecCon	  B:	  protein	  levels	  for	  
GAPDH	  (house	  keeping	  gene)	  and	  DAX-­‐1	  C:	  mRNA	  levels	  for	  DAX-­‐1	  target	  genes	  ERα	  and	  Cyclin	  D1	  as	  well	  as	  downstream	  proliferaCon	  targets	  KI-­‐67	  
(proliferaCon	  marker),	  MCM7	  (essenCal	  for	  genome	  replicaCon),	  and	  TOP2A	  (topoisomerase)	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